disulfiram has been researched along with Breast Neoplasms in 31 studies
Breast Neoplasms: Tumors or cancer of the human BREAST.
| Excerpt | Relevance | Reference |
|---|---|---|
| "A folate-receptor-targeted poly (lactide-co-Glycolide) (PLGA)-Polyethylene glycol (PEG) nanoparticle is developed for encapsulation and delivery of disulfiram into breast cancer cells." | 7.83 | Delivery of disulfiram into breast cancer cells using folate-receptor-targeted PLGA-PEG nanoparticles: in vitro and in vivo investigations. ( Dinarvand, R; Esfandyari-Manesh, M; Faghihi, S; Fasehee, H; Ghaffari, SH; Ghavamzadeh, A; Moradian, H, 2016) |
| "Disulfiram (DSF) is an inhibitor of P-glycoprotein (Pgp), the main obstacle limiting the success of doxorubicin (DOX), but it has poor solubility and stability." | 5.56 | Coencapsulation of disulfiram and doxorubicin in liposomes strongly reverses multidrug resistance in breast cancer cells. ( Arpicco, S; Bincoletto, V; Gazzano, E; Lollo, G; Riganti, C; Rolando, B; Rolle, F; Stella, B, 2020) |
| "Disulfiram (DSF) has exhibited potent autophagy inducing activity in multiple studies." | 5.56 | Disulfiram potentiates docetaxel cytotoxicity in breast cancer cells through enhanced ROS and autophagy. ( Chowdhury, R; Roy, A; Sharma, S; Swetha, KL, 2020) |
| "Disulfiram (DSF) is a drug used clinically for alcoholism treatment that has displayed promising anti-cancer activity in vitro and in cancer xenografts in breast cancer." | 5.51 | Disulfiram modulates ROS accumulation and overcomes synergistically cisplatin resistance in breast cancer cell lines. ( Albers, AE; Guo, F; Kaufmann, AM; Sehouli, J; Yang, Z, 2019) |
| "HER2-positive breast tumors are known to harbor cancer stem-like cell populations and are associated with an aggressive tumor phenotype and poor clinical outcomes." | 5.43 | Disulfiram targets cancer stem-like properties and the HER2/Akt signaling pathway in HER2-positive breast cancer. ( An, H; Cho, TM; Cho, Y; Kim, JY; Lee, N; Oh, E; Seo, JH; Sung, D, 2016) |
| "Triple-negative breast cancer (TNBC) has significantly worse prognosis." | 5.39 | Disulfiram targets cancer stem-like cells and reverses resistance and cross-resistance in acquired paclitaxel-resistant triple-negative breast cancer cells. ( Armesilla, AL; Brown, S; Darling, JL; Jiang, W; Kannappan, V; Kumar, IS; Liu, P; Tang, JZ; Tawari, PE; Wang, W, 2013) |
| "Disulfiram was highly toxic to BC cell lines in vitro in a copper (Cu)-dependent manner." | 5.37 | Disulfiram modulated ROS-MAPK and NFκB pathways and targeted breast cancer cells with cancer stem cell-like properties. ( Armesilla, AL; Brown, S; Cassidy, J; Darling, JL; Fombon, IS; Kannappan, V; Liu, P; Wang, W; Xu, B; Yip, NC, 2011) |
| "Treatment of breast cancer cell lines with a combination of DSF-Cu and LY294002, a pan-PI3K inhibitor, resulted in the significant inhibition of cell growth when compared with either drug alone." | 5.36 | Disulfiram treatment facilitates phosphoinositide 3-kinase inhibition in human breast cancer cells in vitro and in vivo. ( Chen, D; Chen, W; Cui, QC; Dou, QP; Ethier, SP; Ringler, J; Wu, G; Zhang, H, 2010) |
| "In the present study, the preventive effects of orally administered disulfiram (DS) against the doxorubicin (DOX)-induced cardiotoxicity were investigated in rats." | 3.88 | A Chemosensitizer Drug: Disulfiram Prevents Doxorubicin-Induced Cardiac Dysfunction and Oxidative Stress in Rats. ( Bhangale, HA; Chatterjee, S; Chaudhari, SS; Goyal, SN; Kundu, CN; Mahajan, UB; Ojha, S; Patil, CR; Shinde, SD; Sonawane, VK, 2018) |
| "A folate-receptor-targeted poly (lactide-co-Glycolide) (PLGA)-Polyethylene glycol (PEG) nanoparticle is developed for encapsulation and delivery of disulfiram into breast cancer cells." | 3.83 | Delivery of disulfiram into breast cancer cells using folate-receptor-targeted PLGA-PEG nanoparticles: in vitro and in vivo investigations. ( Dinarvand, R; Esfandyari-Manesh, M; Faghihi, S; Fasehee, H; Ghaffari, SH; Ghavamzadeh, A; Moradian, H, 2016) |
| "To investigate: a) whether sub-toxic DSF efficacy can be increased without Cu overload against human melanoma cells with unequal BRAF(V600E) mutant status and Her2-overexpressing SKBR3 breast cancer cells, by increasing H2O2 from exogenous SOD; b) to compare the anti-tumor efficacy of DSF with that of another clinically used copper chelator, tetrathiomolybdate (TTM)." | 3.81 | Disulfiram anti-cancer efficacy without copper overload is enhanced by extracellular H2O2 generation: antagonism by tetrathiomolybdate. ( Calderon-Aparicio, A; Rieber, M; Strasberg-Rieber, M, 2015) |
| "Experimental studies have indicated that disulfiram (Antabuse) has antineoplastic effects against melanoma, breast, and prostate cancer." | 3.80 | Use of disulfiram and risk of cancer: a population-based case-control study. ( Askgaard, G; Friis, S; Hallas, J; Pottegård, A; Thygesen, LC, 2014) |
| "The zinc-ejecting aldehyde dehydrogenase (ALDH) inhibitory drug disulfiram (DSF) was found to be a breast cancer-associated protein 2 (BCA2) inhibitor with potent antitumor activity." | 3.76 | Exploring the structural requirements for inhibition of the ubiquitin E3 ligase breast cancer associated protein 2 (BCA2) as a treatment for breast cancer. ( Brahemi, G; Brancale, A; Buac, D; Burger, AM; Fiasella, A; Kona, FR; Soukupová, J; Westwell, AD, 2010) |
| "Disulfiram (DSF) is an inhibitor of P-glycoprotein (Pgp), the main obstacle limiting the success of doxorubicin (DOX), but it has poor solubility and stability." | 1.56 | Coencapsulation of disulfiram and doxorubicin in liposomes strongly reverses multidrug resistance in breast cancer cells. ( Arpicco, S; Bincoletto, V; Gazzano, E; Lollo, G; Riganti, C; Rolando, B; Rolle, F; Stella, B, 2020) |
| "Disulfiram (DSF) has exhibited potent autophagy inducing activity in multiple studies." | 1.56 | Disulfiram potentiates docetaxel cytotoxicity in breast cancer cells through enhanced ROS and autophagy. ( Chowdhury, R; Roy, A; Sharma, S; Swetha, KL, 2020) |
| "Disulfiram (DSF) is a drug used clinically for alcoholism treatment that has displayed promising anti-cancer activity in vitro and in cancer xenografts in breast cancer." | 1.51 | Disulfiram modulates ROS accumulation and overcomes synergistically cisplatin resistance in breast cancer cell lines. ( Albers, AE; Guo, F; Kaufmann, AM; Sehouli, J; Yang, Z, 2019) |
| "HER2-positive breast tumors are known to harbor cancer stem-like cell populations and are associated with an aggressive tumor phenotype and poor clinical outcomes." | 1.43 | Disulfiram targets cancer stem-like properties and the HER2/Akt signaling pathway in HER2-positive breast cancer. ( An, H; Cho, TM; Cho, Y; Kim, JY; Lee, N; Oh, E; Seo, JH; Sung, D, 2016) |
| "Disulfiram (DSF), which has multi-targeted anti-tumor activity, was encapsulated into redox-sensitive shell crosslinked micelles to achieve intracellular targeted delivery and finally inhibit tumor growth and metastasis." | 1.40 | Multi-targeted inhibition of tumor growth and lung metastasis by redox-sensitive shell crosslinked micelles loading disulfiram. ( Duan, X; Li, Y; Mao, S; Xiao, J; Yin, Q; Yu, H; Zhang, Z, 2014) |
| "Triple-negative breast cancer (TNBC) has significantly worse prognosis." | 1.39 | Disulfiram targets cancer stem-like cells and reverses resistance and cross-resistance in acquired paclitaxel-resistant triple-negative breast cancer cells. ( Armesilla, AL; Brown, S; Darling, JL; Jiang, W; Kannappan, V; Kumar, IS; Liu, P; Tang, JZ; Tawari, PE; Wang, W, 2013) |
| "Disulfiram was highly toxic to BC cell lines in vitro in a copper (Cu)-dependent manner." | 1.37 | Disulfiram modulated ROS-MAPK and NFκB pathways and targeted breast cancer cells with cancer stem cell-like properties. ( Armesilla, AL; Brown, S; Cassidy, J; Darling, JL; Fombon, IS; Kannappan, V; Liu, P; Wang, W; Xu, B; Yip, NC, 2011) |
| "Treatment of breast cancer cell lines with a combination of DSF-Cu and LY294002, a pan-PI3K inhibitor, resulted in the significant inhibition of cell growth when compared with either drug alone." | 1.36 | Disulfiram treatment facilitates phosphoinositide 3-kinase inhibition in human breast cancer cells in vitro and in vivo. ( Chen, D; Chen, W; Cui, QC; Dou, QP; Ethier, SP; Ringler, J; Wu, G; Zhang, H, 2010) |
| "Three human breast cancer cell lines, MCF7/wt, MCF7/adr (multiply drug resistant), and BT474 were grown to confluence, plated into 96 well dishes, and incubated with combinations of drugs for 72h." | 1.31 | In vitro search for synergy and antagonism: evaluation of docetaxel combinations in breast cancer cell lines. ( Budman, DR; Calabro, A, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (3.23) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (6.45) | 29.6817 |
| 2010's | 21 (67.74) | 24.3611 |
| 2020's | 7 (22.58) | 2.80 |
| Authors | Studies |
|---|---|
| Brahemi, G | 1 |
| Kona, FR | 1 |
| Fiasella, A | 1 |
| Buac, D | 1 |
| Soukupová, J | 1 |
| Brancale, A | 1 |
| Burger, AM | 1 |
| Westwell, AD | 2 |
| Zhang, H | 4 |
| Song, F | 1 |
| Dong, C | 1 |
| Yu, L | 1 |
| Chang, C | 2 |
| Chen, Y | 1 |
| Lv, Z | 1 |
| Xue, D | 1 |
| Zhang, T | 2 |
| Jin, L | 1 |
| Cao, Y | 1 |
| Zhang, S | 1 |
| Wang, Y | 1 |
| Solovieva, M | 1 |
| Shatalin, Y | 1 |
| Odinokova, I | 1 |
| Krestinina, O | 1 |
| Baburina, Y | 1 |
| Mishukov, A | 1 |
| Lomovskaya, Y | 1 |
| Pavlik, L | 1 |
| Mikheeva, I | 1 |
| Holmuhamedov, E | 1 |
| Akatov, V | 1 |
| Zhong, Y | 1 |
| Sun, R | 1 |
| Geng, Y | 1 |
| Zhou, Q | 1 |
| Piao, Y | 1 |
| Xie, T | 1 |
| Zhou, R | 1 |
| Shen, Y | 1 |
| Rolle, F | 1 |
| Bincoletto, V | 1 |
| Gazzano, E | 1 |
| Rolando, B | 1 |
| Lollo, G | 1 |
| Stella, B | 1 |
| Riganti, C | 1 |
| Arpicco, S | 1 |
| Swetha, KL | 1 |
| Sharma, S | 1 |
| Chowdhury, R | 1 |
| Roy, A | 1 |
| Solak, K | 1 |
| Mavi, A | 1 |
| Yılmaz, B | 1 |
| Sonawane, VK | 1 |
| Mahajan, UB | 1 |
| Shinde, SD | 1 |
| Chatterjee, S | 1 |
| Chaudhari, SS | 1 |
| Bhangale, HA | 1 |
| Ojha, S | 1 |
| Goyal, SN | 1 |
| Kundu, CN | 1 |
| Patil, CR | 1 |
| Tao, X | 1 |
| Gou, J | 1 |
| Zhang, Q | 1 |
| Tan, X | 1 |
| Ren, T | 1 |
| Yao, Q | 1 |
| Tian, B | 1 |
| Kou, L | 1 |
| Zhang, L | 2 |
| Tang, X | 3 |
| Yang, Z | 1 |
| Guo, F | 1 |
| Albers, AE | 1 |
| Sehouli, J | 1 |
| Kaufmann, AM | 1 |
| Duan, X | 2 |
| Xiao, J | 2 |
| Yin, Q | 2 |
| Zhang, Z | 2 |
| Yu, H | 2 |
| Mao, S | 2 |
| Li, Y | 2 |
| Askgaard, G | 1 |
| Friis, S | 1 |
| Hallas, J | 1 |
| Thygesen, LC | 1 |
| Pottegård, A | 1 |
| Liu, P | 3 |
| Kumar, IS | 1 |
| Brown, S | 3 |
| Kannappan, V | 3 |
| Tawari, PE | 2 |
| Tang, JZ | 2 |
| Jiang, W | 2 |
| Armesilla, AL | 4 |
| Darling, JL | 4 |
| Wang, W | 4 |
| Navrátilová, J | 1 |
| Hankeová, T | 1 |
| Beneš, P | 1 |
| Šmarda, J | 1 |
| Wang, Z | 1 |
| Irache, JM | 1 |
| Wiggins, HL | 1 |
| Wymant, JM | 1 |
| Solfa, F | 1 |
| Hiscox, SE | 1 |
| Taylor, KM | 1 |
| Jones, AT | 1 |
| Yang, Y | 1 |
| Deng, Q | 1 |
| Feng, X | 1 |
| Sun, J | 1 |
| Calderon-Aparicio, A | 1 |
| Strasberg-Rieber, M | 1 |
| Rieber, M | 1 |
| Han, D | 1 |
| Wu, G | 2 |
| Zhu, F | 1 |
| Xiao, Y | 1 |
| Li, Q | 1 |
| Song, W | 1 |
| Tang, Z | 1 |
| Lei, T | 1 |
| Wen, X | 1 |
| Wang, G | 1 |
| Zhang, D | 1 |
| Deng, M | 1 |
| Chen, X | 1 |
| Fasehee, H | 1 |
| Dinarvand, R | 1 |
| Ghavamzadeh, A | 1 |
| Esfandyari-Manesh, M | 1 |
| Moradian, H | 1 |
| Faghihi, S | 1 |
| Ghaffari, SH | 1 |
| Kim, JY | 1 |
| Cho, Y | 1 |
| Oh, E | 1 |
| Lee, N | 1 |
| An, H | 1 |
| Sung, D | 1 |
| Cho, TM | 1 |
| Seo, JH | 1 |
| Jiao, Y | 1 |
| Hannafon, BN | 1 |
| Zhang, RR | 1 |
| Fung, KM | 1 |
| Ding, WQ | 1 |
| Guo, X | 1 |
| Xu, B | 2 |
| Pandey, S | 1 |
| Goessl, E | 1 |
| Brown, J | 1 |
| Chen, D | 2 |
| Ringler, J | 1 |
| Chen, W | 1 |
| Cui, QC | 2 |
| Ethier, SP | 1 |
| Dou, QP | 2 |
| Yip, NC | 1 |
| Fombon, IS | 1 |
| Cassidy, J | 1 |
| Budman, DR | 1 |
| Calabro, A | 1 |
| Yang, H | 1 |
| Lewison, EF | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Phase II Open Labeled Trial of Disulfiram With Copper in Metastatic Breast Cancer[NCT03323346] | Phase 2 | 150 participants (Anticipated) | Interventional | 2017-09-29 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
31 other studies available for disulfiram and Breast Neoplasms
| Article | Year |
|---|---|
Exploring the structural requirements for inhibition of the ubiquitin E3 ligase breast cancer associated protein 2 (BCA2) as a treatment for breast cancer.
Topics: Aldehyde Dehydrogenase; Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Disulfiram; Enzym | 2010 |
Co-delivery of nanoparticle and molecular drug by hollow mesoporous organosilica for tumor-activated and photothermal-augmented chemotherapy of breast cancer.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Copper; Disulfiram; Ditiocarb; D | 2021 |
A Tumor Microenvironment-Responsive Theranostic Agent for Synergetic Therapy of Disulfiram-Based Chemotherapy and Chemodynamic Therapy.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Cell Proliferation; Cell Survival; Disulfiram; Hum | 2021 |
Disulfiram oxy-derivatives induce entosis or paraptosis-like death in breast cancer MCF-7 cells depending on the duration of treatment.
Topics: Antineoplastic Agents; Breast Neoplasms; Disulfiram; Ditiocarb; Duration of Therapy; Entosis; Female | 2022 |
N-Oxide polymer-cupric ion nanogels potentiate disulfiram for cancer therapy.
Topics: Administration, Intravenous; Animals; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplas | 2020 |
Coencapsulation of disulfiram and doxorubicin in liposomes strongly reverses multidrug resistance in breast cancer cells.
Topics: Breast Neoplasms; Cell Survival; Disulfiram; Doxorubicin; Drug Carriers; Drug Resistance, Multiple; | 2020 |
Disulfiram potentiates docetaxel cytotoxicity in breast cancer cells through enhanced ROS and autophagy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Autophagy; Breast Neoplasms; Cell Line, T | 2020 |
Disulfiram-loaded functionalized magnetic nanoparticles combined with copper and sodium nitroprusside in breast cancer cells.
Topics: Breast Neoplasms; Copper; Disulfiram; Humans; Magnetite Nanoparticles; MCF-7 Cells; Nanoparticles; N | 2021 |
A Chemosensitizer Drug: Disulfiram Prevents Doxorubicin-Induced Cardiac Dysfunction and Oxidative Stress in Rats.
Topics: Animals; Antibiotics, Antineoplastic; Antioxidants; Biomarkers; Breast Neoplasms; Cardiotoxicity; Cy | 2018 |
Synergistic breast tumor cell killing achieved by intracellular co-delivery of doxorubicin and disulfiram via core-shell-corona nanoparticles.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Chlorocebus aethiops; COS Cells; | 2018 |
Disulfiram modulates ROS accumulation and overcomes synergistically cisplatin resistance in breast cancer cell lines.
Topics: Acetaldehyde Dehydrogenase Inhibitors; Aldehyde Dehydrogenase; Antineoplastic Agents; Breast Neoplas | 2019 |
Smart pH-sensitive and temporal-controlled polymeric micelles for effective combination therapy of doxorubicin and disulfiram.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Line, Tumor; Delayed | 2013 |
Use of disulfiram and risk of cancer: a population-based case-control study.
Topics: Aged; Alcohol Deterrents; Breast Neoplasms; Case-Control Studies; Denmark; Disulfiram; Female; Human | 2014 |
Disulfiram targets cancer stem-like cells and reverses resistance and cross-resistance in acquired paclitaxel-resistant triple-negative breast cancer cells.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Cisplatin | 2013 |
Acidic pH of tumor microenvironment enhances cytotoxicity of the disulfiram/Cu2+ complex to breast and colon cancer cells.
Topics: Antineoplastic Agents; Breast Neoplasms; Cell Proliferation; Cell Survival; Colonic Neoplasms; Coord | 2013 |
Multi-targeted inhibition of tumor growth and lung metastasis by redox-sensitive shell crosslinked micelles loading disulfiram.
Topics: Animals; Antineoplastic Agents; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; D | 2014 |
Liposome encapsulated Disulfiram inhibits NFκB pathway and targets breast cancer stem cells in vitro and in vivo.
Topics: Animals; Antineoplastic Agents; Blotting, Western; Breast Neoplasms; Cell Line, Tumor; Disulfiram; E | 2014 |
Disulfiram-induced cytotoxicity and endo-lysosomal sequestration of zinc in breast cancer cells.
Topics: Apoptosis; Breast Neoplasms; Cytotoxins; Disulfiram; Dose-Response Relationship, Drug; Endocytosis; | 2015 |
Use of the disulfiram/copper complex for breast cancer chemoprevention in MMTV-erbB2 transgenic mice.
Topics: Animals; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Chemoprevention; Copper; Cyclin D1; | 2015 |
Disulfiram anti-cancer efficacy without copper overload is enhanced by extracellular H2O2 generation: antagonism by tetrathiomolybdate.
Topics: Acetylcysteine; Antineoplastic Agents; Blotting, Western; Breast Neoplasms; Cell Line, Tumor; Cell S | 2015 |
Disulfiram inhibits TGF-β-induced epithelial-mesenchymal transition and stem-like features in breast cancer via ERK/NF-κB/Snail pathway.
Topics: Alcohol Deterrents; Animals; Apoptosis; Blotting, Western; Breast Neoplasms; Cell Cycle; Cell Moveme | 2015 |
Stable loading and delivery of disulfiram with mPEG-PLGA/PCL mixed nanoparticles for tumor therapy.
Topics: Acetaldehyde Dehydrogenase Inhibitors; Alcohol Deterrents; Animals; Antineoplastic Agents; Breast; B | 2016 |
Delivery of disulfiram into breast cancer cells using folate-receptor-targeted PLGA-PEG nanoparticles: in vitro and in vivo investigations.
Topics: Breast Neoplasms; Cell Line, Tumor; Cell Survival; Disulfiram; Drug Carriers; Female; Folate Recepto | 2016 |
Disulfiram targets cancer stem-like properties and the HER2/Akt signaling pathway in HER2-positive breast cancer.
Topics: Acetaldehyde Dehydrogenase Inhibitors; Aldehyde Dehydrogenase; Aldehyde Dehydrogenase 1 Family; Anim | 2016 |
Docosahexaenoic acid and disulfiram act in concert to kill cancer cells: a mutual enhancement of their anticancer actions.
Topics: Antineoplastic Agents; Apoptosis; Breast Neoplasms; Cell Proliferation; Cell Survival; Disulfiram; D | 2017 |
Disulfiram/copper complex inhibiting NFkappaB activity and potentiating cytotoxic effect of gemcitabine on colon and breast cancer cell lines.
Topics: Antineoplastic Agents; Blotting, Western; Breast Neoplasms; Cell Line, Tumor; Colonic Neoplasms; Cop | 2010 |
Disulfiram treatment facilitates phosphoinositide 3-kinase inhibition in human breast cancer cells in vitro and in vivo.
Topics: Animals; Breast Neoplasms; Cell Line, Tumor; Chromones; Class I Phosphatidylinositol 3-Kinases; Copp | 2010 |
Disulfiram modulated ROS-MAPK and NFκB pathways and targeted breast cancer cells with cancer stem cell-like properties.
Topics: Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Copper; Disulfiram; Electrophoretic Mobil | 2011 |
In vitro search for synergy and antagonism: evaluation of docetaxel combinations in breast cancer cell lines.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplasti | 2002 |
Disulfiram, a clinically used anti-alcoholism drug and copper-binding agent, induces apoptotic cell death in breast cancer cultures and xenografts via inhibition of the proteasome activity.
Topics: Animals; Apoptosis; Breast Neoplasms; Chymotrypsin; Copper; Disulfiram; Female; Humans; Mice; Neopla | 2006 |
Spontaneous regression of breast cancer.
Topics: Adult; Alcohol Drinking; Breast Neoplasms; Disulfiram; Female; Goiter; Humans; Malaria; Male; Middle | 1977 |